Connect with us

Press Releases

Upneeq Win’s 2021 Allure Best of Beauty Breakthrough Award

Upneeq is an FDA-approved prescription eye drop to treat adults with acquired blepharoptosis (low-lying eyelids).




(PRESS RELEASE) BRIDGEWATER, N.J. — RVL Pharmaceutical’s Upneeq eye drops, which temporarily lift low-lying eyelids, was presented with a 2021 Best of Beauty Breakthrough Award by Allure Magazine. The award has been globally recognized as one of the most distinguished beauty awards by both industry professionals and consumers since its launch in the mid-1990s.

Editors at Allure spend months reviewing clinical data and gathering opinions from independent judges, evaluating the quality of the product and determining whether it is truly a breakthrough. Of the 2021 winners, Allure wrote, “We present seven of the most revolutionary innovations we’ve ever seen — ones that have changed the way we approach beauty. These new products boggled our editors’ minds and forever changed our beauty routines.”

Upneeq is an FDA-approved prescription eyedrop for the treatment of acquired blepharoptosis (low-lying lids) in adults. Before Upneeq, the only option for patients with ptosis wanting to truly lift their eyelids was correction surgery. Now, one drop of Upneeq can temporarily raise a patient’s lid (average lift in clinical trials was 1mm with some patients experiencing lift up to 3mm). For patients with acquired ptosis, Upneeq can have a noticeable difference, changing the game for eye care professionals seeking to provide complete care for their patients.

“We are grateful to receive this important award and excited that the ground-breaking innovation in Upneeq is being recognized,” said Dr. Ray Douglas, an aesthetic reconstructive and oculoplastic specialist and Global Head of Scientific Affairs for RVL Pharmaceuticals. “Until Upneeq, there was no pharmacologic treatment on the market. RVL is passionate about continuing to provide novel solutions for both vision and aesthetics.”

The active ingredient in Upneeq (0.1% oxymetazoline hydrochloride ophthalmic solution) triggers the levator muscle, causing it to contract and lift the eyelid. The dosage is one drop a day per affected eye. In clinical trials, some patients reported an improvement in as little as five minutes, and full results took effect after two hours.

“Millions of Americans may suffer from an often undiagnosed or overlooked condition called ‘acquired blepharoptosis,’ also known as acquired ptosis or ‘droopy eyelids’,” says Dr. Douglas. “The condition not only affects the aesthetics of the face, but may also cause vision impairment that interferes with day-to-day functions such as reading and driving. We are excited to offer a noninvasive option to increase eyelid lift.”


Visit Upneeq to learn more about the award-winning drops. See below for Important Safety Information.

To read the Allure 2021 Best of Beauty Breakthrough Awards article, click here.






Get the most important news and business ideas for eyecare professionals every weekday from INVISION.


Most Popular